Patents Examined by James L. Grun
  • Patent number: 9372190
    Abstract: The present invention relates to a method for determining the amount of circulating CD36 protein or a fraction thereof which is present in cell-free plasma, preferably in a high molecular weight plasma fraction, such as a lipoprotein fraction selected from Low Density Lipoprotein, Intermediate Density Lipoprotein, and Very Low Density Lipoprotein using an immunological method which comprises the steps of (i) providing a plasma sample to be investigated, (ii) providing an anti-CD36 antibody, (iii) exposing the sample to be investigated to the antibody, and (iv) detecting and quantifying the amount of CD36 which binds to the antibody.
    Type: Grant
    Filed: May 26, 2005
    Date of Patent: June 21, 2016
    Assignee: Region Nordjylland
    Inventor: Aase Handberg
  • Patent number: 9371382
    Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like.
    Type: Grant
    Filed: September 19, 2011
    Date of Patent: June 21, 2016
    Assignee: Nexus DX, Inc.
    Inventors: Michelle Davey, George Jackowski, Peter Kupchak, Eric Stanton
  • Patent number: 9371394
    Abstract: Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of a phosphinothricin-N-acetyl-transferase enzyme. The claimed antibodies and methods are particularly useful for identifying and quantitating the presence of phosphinothricin-N-acetyl-transferase expressed in trangenic plants.
    Type: Grant
    Filed: October 9, 2013
    Date of Patent: June 21, 2016
    Assignee: Dow AgroSciences LLC
    Inventors: Guomin Shan, Eric H. Ma
  • Patent number: 9366680
    Abstract: The present invention provides a method and an index capable of less-invasively determining myocardial ischemia such as ischemic heart disease or restenosis after percutaneous coronary intervention. The present invention also provides an index that allows the cardiovascular disease other than heart failure to be determined even from a blood sample showing a BNP value from which the cardiovascular disease other than heart failure cannot be determined by a conventional method.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: June 14, 2016
    Assignees: SHIMADZU CORPORATION, THE UNIVERSITY OF TOKYO
    Inventors: Hirotaka Fujimoto, Toru Suzuki
  • Patent number: 9341623
    Abstract: A method for performing an immunodiffusion assay comprising at least the following steps of: (a) preparing one or more test samples comprising an influenza virus antigen, (b) treating the test samples with at least 5% (w/v) of detergent, (c) applying the treated test samples to a gel comprising an antibody specific to the influenza virus antigen, and (d) allowing the samples to diffuse into the gel.
    Type: Grant
    Filed: September 23, 2010
    Date of Patent: May 17, 2016
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Benoit Guy Jules Baras, Valerie Audry Micheline Jacob
  • Patent number: 9341633
    Abstract: There are provided a pre-treatment technique for a glycated hemoglobin-containing sample, which is a simple and convenient treatment, is free from problems in storage stability and environmental aspects, and is capable of exposing an epitope sufficiently in a short time; and an method for an immunological assay of glycated hemoglobin using this technique. A method for pre-treating a glycated hemoglobin-containing sample for an immunological assay of glycated hemoglobin, the method includes treating a glycated hemoglobin-containing sample with a pre-treatment solution containing (A) guanidine or a salt thereof and (B) a nonionic surfactant and/or a nitrite.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: May 17, 2016
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Osamu Miyazaki, Syunsuke Kurashita, Kohei Takubo
  • Patent number: 9335329
    Abstract: The present invention pertains to a diagnostic assay for the diagnosis of an autoimmune disease. The present invention provides an improved diagnostic assay for the diagnosis of an autoimmune disease, particularly rheumatoid arthritis (RA) and Systemic Lupus Erythematosus (SLE). In particular the invention pertains to a method of determining in a sample of a subject the presence of two or more antibodies comprising the step of determining whether an antibody is present in a sample that specifically recognizes a hnRNP-DL polypeptide or a fragment thereof or a splice variant thereof and the further step of determining whether at least one further antibody is present in the sample that specifically recognizes a at least one other hnRNP polypeptide which is not sequence homologue to said hnRNP-DL polypeptide or fragments thereof or splice variants thereof, and/or said CCP peptide and/or a polypeptide comprising at least the Fc-part of IgG, respectively.
    Type: Grant
    Filed: December 18, 2009
    Date of Patent: May 10, 2016
    Assignees: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V, Charité—Universitätsmedizin Berlin
    Inventors: Zoltán Konthur, Hans Lehrach, Karl Skriner
  • Patent number: 9329180
    Abstract: The present invention provides a method for preparing an isolated eukaryotic cell which presents an anti-polyethylene glycol (PEG) antibody on a cell membrane. The present invention also provides a method for a quantitative analysis of a polyethylene glycol (PEG) by said anti-PEG antibody expressing cell. The cell-based quantitative analysis of the present prevention could sensitively quantify free PEG and PEG-modified macromolecules (proteins, nanoparticles and liposomes) as sensitive as nano-gram level.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: May 3, 2016
    Assignee: KAOHSIUNG MEDICAL UNIVERSITY
    Inventors: Tian-Lu Cheng, Steven R. Roffler, Kuo-Hsiang Chuang, Ssu-Jung Lu
  • Patent number: 9321846
    Abstract: Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-? and was developed to treat TNF-? mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: April 26, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD.
    Inventors: Zehra Kaymakcalan, Limin Xiong
  • Patent number: 9315583
    Abstract: The invention provides methods and reagents useful for detecting anti-drug antibodies of IgE isotype to therapeutic anti-IgE antibodies, and methods for assessing risk of anaphylaxis to administration of a therapeutic anti-IgE antibody.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: April 19, 2016
    Assignee: Genentech, Inc.
    Inventors: Saloumeh Fischer, Dana L. Baker, Henry B. Lowman, Gerald R. Nakamura
  • Patent number: 9309312
    Abstract: An object of the present invention is to detect a human CXCL1 protein with high sensitivity. An immunoassay method is provided for a human CXCL1 protein, by which human CXCL1 or a fragment thereof in a sample is measured using two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof, wherein: each of the two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof specifically recognizes any one of sequence regions of the amino acid sequences shown in SEQ ID NOS: 1-3, which are partial sequences of the amino acid sequence composing a human CXCL1 protein; and the two or more types of anti-human CXCL1 monoclonal antibodies or fragments thereof specifically recognize sequence regions that differ from each other. Monoclonal antibodies or fragments thereof are provided, each of which specifically recognizes any one sequence region of the amino acid sequences shown in SEQ ID NOS: 1-3 and has a new amino acid sequence.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: April 12, 2016
    Assignee: TORAY INDUSTRIES, INC.
    Inventors: Satoko Kanamori, Giman Jung, Yoshinori Tanaka, Aiko Takayama
  • Patent number: 9250248
    Abstract: The present invention is based on the discovery that hexosamine, and in particular the dynamic O-GlcNAcylation of proteins (modification of proteins by the sugar N-acetylglucosamine) both causes insulin-resistance (a hallmark of type II diabetes) and is responsible for glucose toxicity in the disease. Accordingly, the invention provides methods of diagnosing a subject as having or at risk of having pre-diabetes or diabetes. Also provided are methods of characterizing hyperglycemia in a subject, methods of identifying a protein as being associated with hyperglycemia, and kits for detecting pre-diabetes or diabetes.
    Type: Grant
    Filed: October 31, 2007
    Date of Patent: February 2, 2016
    Assignee: The Johns Hopkins University
    Inventors: Gerald W. Hart, Kyoungsook Park, Christopher D. Saudek, Zihao Wang
  • Patent number: 9222942
    Abstract: Described herein are method(s), kit(s), reagent(s) and the like for determining von Willebrand factor (VWF) activity in a sample in the absence of ristocetin.
    Type: Grant
    Filed: January 6, 2010
    Date of Patent: December 29, 2015
    Assignee: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventors: Harald Althaus, Tobias Obser, Juergen Patzke, Reinhard Schneppenheim
  • Patent number: 9201078
    Abstract: The invention relates to low wash Thyroid Stimulating Hormone (TSH) immunoassays using an ELISA sandwich assay having limited or no wash step between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: December 1, 2015
    Assignee: Abbott Point of Care Inc.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Patent number: 9199234
    Abstract: The invention relates to antibody characteristics used to design a whole blood Point of Care Thyroid Stimulating Hormone (TSH) immunoassay using an ELISA sandwich assay lacking one or more wash steps between the antigen capture, detection antibody addition and substrate introduction steps. This invention exhibits low cross reactivity with biologically similar interfering cross reacting species, such as Follicle Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Chorionic Gonadotropin (CG).
    Type: Grant
    Filed: November 29, 2011
    Date of Patent: December 1, 2015
    Assignee: Abbott Point of Care Inc.
    Inventors: Dan Wang, Gordon Bruce Collier, Joseph P. Skinner, Qiaoqiao Ruan, Sergey Y. Tetin
  • Patent number: 9201077
    Abstract: Compositions, methods and kits for determining progesterone levels in mares are disclosed.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 1, 2015
    Assignee: Colorado State University Research Foundation
    Inventors: Terry M. Nett, Patrick M. McCue, Ryan M. Brooks, Jason E. Bruemmer, David J. Denniston
  • Patent number: 9169320
    Abstract: Provided is a general-purpose technique capable of measuring the HbA1c content, which is comparable to the IFCC reference method. An antibody which reacts with a peptide or a protein having an amino acid sequence of VHLTPE (SEQ ID NO: 1) at the N-terminus in which the N-terminal valine is not modified, but does not react with a peptide or a protein in which the N-terminal valine of the relevant polypeptide or protein is modified.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: October 27, 2015
    Assignee: SEKISUI MEDICAL CO., LTD.
    Inventors: Osamu Miyazaki, Kohei Takubo, Syunsuke Kurashita
  • Patent number: 9163081
    Abstract: It is intended to provide an antibody which inhibits the function of midkine. An antibody which recognizes an epitope consisting of amino acid residues 62 to 104 of midkine or a fragment thereof; DNA encoding the antibody or a fragment thereof; a recombinant vector which contains the DNA; a transformant which has the vector or a hybridoma which produces the antibody; a method for producing the antibody by allowing the transformant or hybridoma to produce the antibody or a fragment thereof and collecting the resulting antibody or fragment thereof; a pharmaceutical composition containing the antibody or a fragment thereof as an active ingredient; and a diagnostic agent containing the antibody or a fragment thereof as an active ingredient.
    Type: Grant
    Filed: November 13, 2007
    Date of Patent: October 20, 2015
    Assignee: Medical Therapies Limited
    Inventors: Takashi Matsui, Takashi Muramatsu, Masatoshi Hayashibara, Takanori Ito, Tsukasa Uno, Sadatoshi Sakuma
  • Patent number: 9140709
    Abstract: The present invention concerns an immunological test for determining NT-proBNP comprising at least two antibodies to NT-proBNP, wherein at least one of the antibodies to NT-proBNP is a monoclonal antibody. The epitopes recognized by the antibodies can slightly overlap.
    Type: Grant
    Filed: January 15, 2009
    Date of Patent: September 22, 2015
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Juergen Spinke, Alfons Nichtl, Volker Klemt, Klaus Hallermayer, Michael Grol, Anneliese Borgya, Andreas Gallusser
  • Patent number: 9140707
    Abstract: A method for generating antibodies preferable to either a normal protein and a mutated form of the normal protein, respectively, where a mutation associated with the mutated form includes either a single point mutation or a small number of point mutations where the method includes creating first and second antigenic peptides of a predetermined length corresponding respectively to common regions of the normal target protein and the mutated form, where the common regions are identical to one another except for the point mutation of the mutated form, obtaining first and second antibodies by multiplying the first and second antigenic peptides via hybridoma methods, and identifying the respective affinities of the first and second antibodies for the normal target protein and the mutated form. Also included are methods of using the first and second antibodies to detect and quantify respective amounts of a normal target protein and a mutated form of the target protein.
    Type: Grant
    Filed: August 10, 2007
    Date of Patent: September 22, 2015
    Assignee: University of Louisville Research Foundation, Inc.
    Inventors: Kyung Aih Kang, Stephen Peiper